鞘氨醇激酶1在乳腺癌骨髓中的表达及临床意义*

Expression of sphingosine kinase-1 in bone marrow of breast cancer and its clinical significance*

摘要:

目的 探讨鞘氨醇激酶1（SPHK1）在乳腺癌患者骨髓中的表达及临床意义。方法 选取2016年6月—2018年6月长沙市第一医院诊治的90例乳腺癌患者、52例乳腺良性肿瘤及20例健康体检者骨髓，采用实时荧光定量聚合酶链反应（qRT-PCR）及Western blotting检测骨髓中SPHK1的表达。结果 90例乳腺癌患者中骨髓SPHK1阳性68例（75.6%），高于良性乳腺肿瘤组（13.5%）及健康对照组（5.0%）（P?<0.05）；乳腺癌患者SPHK1 mRNA表达水平高于良性乳腺肿瘤患者和健康对照组（P?<0.05）；乳腺癌患者SPHK1蛋白含量为（1.657±0.198），高于良性乳腺肿瘤组患者（0.963±0.132）和健康对照组（0.749±0.128）（P?<0.05）；以病理活检为金标准，骨髓SPHK1诊断敏感性为75.6%，特异性为86.5%。经Kappa检验κ值为0.59，具有较好的一致性。结论 乳腺癌患者骨髓中SPHK1表达升高，SPHK1的检测有助于早期检测乳腺癌患者的骨髓转移。

Abstract:

Objective To investigate the expression of sphingosine kinase 1 (SPHK1) in bone marrow of patients with breast cancer and its clinical significance. Methods Bone marrow samples were collected from 90 patients with breast cancer, 50 patients with benign breast tumors and 20 healthy persons. The expression of SPHK1 in bone marrow was detected by real-time fluorescence quantitative polymerase chain reaction (qRT-PCR) and Western blotting method. Results In 90 cases of breast cancer, 68 cases (75.6%) were SPHK1 positive in bone marrow, which was higher than that in benign breast cancer group (13.5%) and healthy control group (5.0%) (P?< 0.05); the expression of SPHK1 mRNA in breast cancer patients was significantly higher than that in benign breast cancer patients and healthy control group (P? 0.40 tested by Kappa test, which showed good consistency. Conclusions SPHK1 can be used as a molecular marker of bone marrow metastasis in breast cancer patients, which is helpful for early detection of bone marrow metastasis in breast cancer patients.